MuReva Phototherapy

MuReva’s mission is to create oral phototherapy devices that are inherently-safe, patient-friendly and clinically-proven to improve the quality of life and clinical outcomes for patients receiving radiation and chemotherapy for the treatment of cancer.

Clinical findings showed fewer patients developing severe OM, fewer days with severe OM and less pain, along with favorable findings in treatment continuity.

MuReva says privacy is important and provides this policy because it is sensitive to privacy issues on the internet.

MuReva Phototherapy announced that the American Medical Association’s CPT Editorial Panel approved Category III CPT code 1011T for procedures associated with the company’s proprietary intraoral LED-based photobiomodulation devices. Effective January 1, 2026, the code covers photobiomodulation delivery to the oral cavity and is intended to support reimbursement and broader patient access for treatment of radiation- and chemotherapy-induced oral mucositis.

Dec 2025MuReva PhototherapyNews article

MuReva Phototherapy presents clinical data at the 2025 ASTRO Meeting showing its LED-based photobiomodulation therapy device is safe and reduces severe oral mucositis in head and neck cancer patients receiving radiation. The U.S. multicenter study includes 85 patients randomized to MuReva OM intra-oral treatment or sham control, and reports good tolerability and significant reductions in severe oral mucositis during radiation and two weeks after treatment.

Oct 2025MuReva PhototherapyNews article

MuReva Phototherapy presents pilot-study data on its intraoral photobiomodulation device in 36 head and neck cancer patients receiving intensity-modulated radiation therapy. Across seven sites, the company reports reduced oral mucositis severity and retention of salivary flow and swallowing ability. Treatment is well tolerated: 97% of treatments are completed in full, no device-related adverse events are reported, and 97% of subjects are satisfied with their experience.

Oct 2023MuReva PhototherapyNews article

MuReva Phototherapy presents pilot-study data on its LED-based intraoral photobiomodulation device for head and neck cancer patients receiving radiation therapy. The study reports reduced oral mucositis severity and retention of salivary flow and swallowing ability; 97% of treatments are completed in full, with no device-related adverse events and 97% of subjects satisfied.

Jun 2023MuReva PhototherapyNews article